Regulatory approval

Published by the Health Service Executive. Approved

Obinutuzumab in combination with CVP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Obinutuzumab - ODMS 2019-05-01; cyclophosphamide and vincristine - N/A

Citation

Obinutuzumab cycloPHOSphamide vinCRIStine and prednisoLONE (O-CVP) Therapy - 21 day, Year, version number 3, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8394/550_obinutuzumab_CVP_550.pdf

View API

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations Biomarkers Cancer types Therapies
HSE (1) CD20 + Follicular Lymphoma Cyclophosphamide, Obinutuzumab, Prednisolone, Vincristine